AstraZeneca Board Meeting Scheduled to Approve Unaudited Financial Results

AstraZeneca Pharma India Limited has announced a meeting of its Board of Directors on Friday, November 7, 2025. The purpose of the meeting is to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2025. The trading window remains closed from September 16, 2025 to November 9, 2025.

Board Meeting Announcement

AstraZeneca Pharma India Limited has scheduled a meeting of its Board of Directors to be held on Friday, November 7, 2025. During this meeting, the board will review and approve the company’s unaudited financial results.

Financial Results Review

The primary agenda of the board meeting is to consider and approve the unaudited financial results for the quarter and half year which concluded on September 30, 2025. This review will provide insights into the company’s financial performance for Q2 of fiscal year 2026.

Trading Window Closure

The company has also announced the closure of its ‘Trading Window’. Trading will remain suspended for designated persons from September 16, 2025 to November 9, 2025 (inclusive). This closure is in accordance with AstraZeneca Pharma India Limited’s code of conduct for prevention of insider trading.

Source: BSE

InvestyWise News
InvestyWise News
Covers market-moving news with speed and precision, delivering sharp insights to help readers stay ahead in the fast-paced world of stocks.

Latest articles

Related articles

Leave a reply

Please enter your comment!
Please enter your name here
Captcha verification failed!
CAPTCHA user score failed. Please contact us!